TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31177181
Drug: Habitual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual daily physical activity (measured by total physical activity counts - TAC)
Study: 18564231
Drug: tolterodine-ER 4
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine-ER 4 mg
Study: 15331567
Drug: Oral trientine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trientine therapy for 7 weeks in diabetic rats
Study: 15331567
Drug: Oral trientine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trientine treatment for 6 months in humans with type 2 diabetes
Study: 15331567
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Cu-selective transition metal chelator trientine
Study: 10819335
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (twice weekly for 6 months) with isoniazid 15 mg/kg/dose, rifampin 15 mg/kg/dose, and pyrazinamide 55 mg/kg/dose for 2 months, followed by isoniazid and rifampin only for 4 months.
Study: 10819335
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment (weekday) with isoniazid 10 mg/kg/day, rifampin 10 mg/kg/day, and pyrazinamide 25 mg/kg/day for 6 months.
Study: 6352280
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) 75 mg/m2, administered i.v. bolus every 3 weeks
Study: 6352280
Drug: Carminomycin (CMM)
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carminomycin (CMM) 20 mg/m2, administered i.v. bolus every 3 weeks
Study: 31146774
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at nine acupuncture points (GV20, EX-HN1, bilateral LI4, and ST36) twice a week for 12 weeks
Study: 31146774
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment at the same points with non-penetrating sham needles
Study: 21375669
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 µg
Study: 21375669
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin 20 units
Study: 19075271
Drug: Oregovomab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregovomab (2 mg infused over 20 minutes at weeks 0, 4, and 8, then every 12 weeks until recurrence or up to year 5)
Study: 17848834
Drug: RAI+rhTSH (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAI+rhTSH (0.45 mg of rhTSH prior to treatment)
Study: 17848834
Drug: RAI (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAI (no rhTSH pre-treatment)
Study: 15377348
Drug: ALA-PDT treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT treatment
Study: 11855664
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day + Vitamin E 600 IU/day (G5)
Study: 11855664
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (G4)
Study: 25432877
Drug: Daily emtricitabine/tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emtricitabine/tenofovir
Study: 24377213
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupuncture and moxibustion
Study: 24377213
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (glucosamine sulfate capsules and joint cavity injections)
Study: 14557011
Drug: Cyclogest vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclogest vaginal suppositories 400mg twice daily
Study: 14557011
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% vaginal gel once daily
Study: 30564971
Drug: Pharmacy-led intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacy-led intervention to improve medication adherence
Study: 30564971
Drug: Belief About
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belief About Medicines Questionnaire-Specific
Study: 27053383
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HS and MNP
Study: 19597520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no training or additional therapy)
Study: 18455656
Drug: Soy (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (50 g daily)
Study: 18455656
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (3 g in 500 mL of water daily)
Study: 18455656
Drug: Soy (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (50 g daily) and Green tea (3 g daily)
Study: 354615
Drug: Intravenous droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous droperidol (Inapsine)
Study: 30573159
Drug: Annurca apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annurca apple polyphenolic extract (AMS), 4 capsules/day for 24 weeks
Study: 30573159
Drug: Placebo (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin capsules)
Study: 26655129
Drug: OAC-1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-1 group (1 week treatment with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg bid)
Study: 26655129
Drug: OAC-2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-2 group (2 weeks treatment with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg bid)
Study: 26655129
Drug: OAC-1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-1 group (1 week treatment)
Study: 26655129
Drug: OAC-2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-2 group (2 weeks treatment)
Study: 16513521
Drug: Dosing adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing adjusted for the source‐to‐target distance (DA group)
Study: 16513521
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose prescription protocol (S group)
Study: 12602655
Drug: Antidepressant medication;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication; effectiveness assessed through factor analysis; specific dosage and duration not mentioned.
Study: 11493096
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of saline spa water and UV‐B therapy (group C)
Study: 9612329
Drug: L‐NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (3 mg/kg over 10 min) during high sodium intake (250 mmol/day)
Study: 9612329
Drug: L‐NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (3 mg/kg over 10 min) during low sodium intake (77 mmol/day)
Study: 8296408
Drug: Erythropoietin albumin-solution
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin albumin-solution
Study: 7984241
Drug: Bisdioxopiperazines (topoisomerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisdioxopiperazines (topoisomerase II inhibitors) such as ICRF-193
Study: 7984241
Drug: Caffeine (checkpoint-evading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (checkpoint-evading agent)
Study: 19249998
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (12-week, twice-weekly sessions including asanas and visama vritti pranayama)
Study: 15078254
Drug: Plasmapheresis (37,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (37, 16, and 10 l annually)
Study: 11966951
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy for 2 years
Study: 10325999
Drug: 2.5% topical
Normalized name: BP 2.5% Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% topical aqueous phenylephrine
Study: 10325999
Drug: 10% topical
Normalized name: BP 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% topical aqueous phenylephrine
Study: 7584198
Drug: Cryo/Cuff (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo/Cuff (CC)
Study: 7584198
Drug: Ice therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ice therapy (ICE)
Study: 31096036
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 250/50 μg
Study: 28838473
Drug: Polymer-free biolimus
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer-free biolimus A9 drug-coated stents (DCS)
Study: 14738771
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of upright and inverted face processing
Study: 11092071
Drug: Regular substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular substance abuse treatment programs
Study: 3102303
Drug: Best oral
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best oral feeding
Study: 29653635
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g omega-3 FA daily
Study: 28281457
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg/day
Study: 23717490
Drug: BMS-936558 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936558 (0.1 mg/kg or 10 mg/kg)
Study: 23717490
Drug: BMS-936558 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936558 (10 mg/kg)
Study: 8661976
Drug: Intranasal synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal synthetic SCT (200 IU daily)
Study: 8661976
Drug: Thrice-weekly calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly calcitonin
Study: 1804669
Drug: Almitrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (100 mg.day-1, intermittent schedule)
Study: 6289963
Drug: Ceftriaxone 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 62.5 mg
Study: 6289963
Drug: Ceftriaxone 32.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 32.5 mg
Study: 6289963
Drug: Kanamycin 2
Normalized name: kanamycin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin 2 g
Study: 25855073
Drug: Postoperative drug
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative drug therapy to prevent disease recurrence
Study: 23980084
Drug: Brivanib 800
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib 800 mg once daily orally
Study: 23980084
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily orally
Study: 11055474
Drug: Candesartan cilexetil/hydrochlorothiazide
Normalized name: Candesartan Cilexetil/Hydrochlorothiazide 32 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg)
Study: 11055474
Drug: Losartan/hydrochlorothiazide (losartan/HCT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/hydrochlorothiazide (losartan/HCT; 50/12.5 mg)
Study: 8379551
Drug: Cognitive-behavioral program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral program (10 weeks of group therapy)
Study: 8379551
Drug: Slow taper
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow taper condition alone
Study: 2875594
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg-droperidol 5 mg
Study: 29665102
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae
Study: 29665102
Drug: Standard-of-care (SOC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC, no antibiotics/FMT)
Study: 16181465
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil (5-FU) cream applied twice daily for 3 weeks
Study: 16181465
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil (5-FU) cream applied twice daily for 1 day per week for 12 weeks
Study: 12680810
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (T2) - Communicative Reading Strategies (CRS)
Study: 12680810
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 (T1) - Traditional decoding‐based feedback strategies
Study: 10686664
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 x 1 g daily for 120 days)
Study: 8836270
Drug: Propofol (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (15-20 mg/kg.h) with 30% O2 in air
Study: 8836270
Drug: Propofol (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (10-15 mg/kg.h) with 30% O2 in N2O
Study: 1364936
Drug: Plain naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain naproxen tablets (PT)
Study: 22954919
Drug: Multi-frequency low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multi-frequency low-dose intravenous iron (iron sucrose 25 mg, twice a week for 8 weeks)
Study: 22954919
Drug: Less-frequency regular-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-frequency regular-dose intravenous iron (iron sucrose 100 mg, once every two weeks for 8 weeks)
Study: 12401757
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg b.i.d.
Study: 12401757
Drug: Glyburide (GLB)
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (GLB) titrated to mean 10.5 mg/day for the first 8 weeks
Study: 10350385
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g every 12 h for a minimum of 3 days and up to 14 days
Study: 10350385
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g every 12 h for a minimum of 3 days and up to 14 days
Study: 9166486
Drug: Conventional supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional supportive treatment alone
Study: 1613829
Drug: 0.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/day rhGH
Study: 27893130
Drug: Inpatient palliative
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient palliative care (n=81), seen by palliative care clinicians at least twice a week during HCT hospitalization.
Study: 20208067
Drug: Individual characteristics
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual characteristics (e.g., choice of general practitioner, male gender, age)
Study: 17389624
Drug: Enoxaparin (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.67 +/- 0.14 mg/kg)
Study: 17389624
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH, bolus of 1500 IU followed by infusion of 2750 IU)
Study: 15549327
Drug: 5-FU 450
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles (arm A)
Study: 15549327
Drug: 24-h infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications (arm B)
Study: 15549327
Drug: 24-h infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications (arm C)
Study: 9928771
Drug: Analgesic treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic treatment (non-opioid or opioid analgesics, antidepressants, anticonvulsants, corticosteroids)
Study: 9928771
Drug: Palliative antineoplastic
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative antineoplastic treatment
Study: 28601567
Drug: All evidence-based
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All evidence-based measures (prophylactic antibiotics within 60 minutes of cesarean delivery, chlorhexidine-alcohol for skin antisepsis, closure of subcutaneous layer if ≥2 cm, subcuticular skin closure with suture)
Study: 17937565
Drug: Dietary soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary soy supplements (part of a randomized, placebo-controlled trial)
Study: 15743397
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (200 mg over a 3 h period)
Study: 11990732
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 200 mg/week, intramuscularly for 8 weeks
Study: 9655532
Drug: Azithromycin (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (oral, for 5 days)
Study: 9655532
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, for 5 days)
Study: 7653817
Drug: 3‐in‐1 block
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐in‐1 block with 40 mL of 1.5% lidocaine plus epinephrine (n = 13)
Study: 7653817
Drug: 3‐in‐1 block
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐in‐1 block with 50 mL of 1.5% lidocaine plus epinephrine (n = 11)
Study: 7653817
Drug: Direct obturator
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct obturator nerve block with 10 mL of 2% lidocaine plus epinephrine (n = 20)
Study: 2683439
Drug: Continuous application
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous application of 0.1% fluprednidene-21-acetate twice a day
Study: 2683439
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with 1 day intermission (15 patients)
Study: 2683439
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with 2 days intermission (16 patients)
Study: 2683439
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with 3 days intermission (13 patients)
Study: 2683439
Drug: Fluprednidene treatment
Normalized name: fluprednidene
DrugBank: Fluprednidene acetate (DB14634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluprednidene treatment in eczema patients
Study: 335225
Drug: Combined calcium
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined calcium and vitamin D‐2 phosphate treatment
Study: 335225
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and phosphate treatment
Study: 31399438
Drug: Liraglutide (≤1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (≤1.8 mg daily; n = 4,668)
Study: 26348751
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of elemental iron (as ferrous fumarate)
Study: 22684652
Drug: Micronutrient cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient cocktail containing physiological doses of antioxidant vitamins and trace minerals
Study: 17107402
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg plus montelukast 10 mg
Study: 17107402
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg plus placebo
Study: 15174894
Drug: Oral modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral modified-release clarithromycin 500 mg/day for 3 months
Study: 9248762
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP-DH) cortisol suppression 12-24 h after last dose
Study: 9248762
Drug: Budesonide (BUD-TBH)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD-TBH) cortisol suppression 12-24 h after last dose
Study: 24188897
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (100mg elemental Zn daily for 60 days)
Study: 20846599
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg maintenance dose (MD)
Study: 20846599
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg maintenance dose (MD)
Study: 20846599
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (LD) + 10 mg maintenance dose (MD)
Study: 20846599
Drug: Prasugrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel loading dose (LD)
Study: 18718780
Drug: Subantimicrobial doses
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial doses of doxycycline for 6 months